Rituxan Rituximab - 100mg Vial for Intravenous Use
Rituxan Rituximab - 100mg Vial for Intravenous Use
Previous
Next
Usage conditions apply
- Description (Brief)
- (From box) For single-use IV administration only.
- (From insert)
- RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of patients with:
- --Non-Hodgkin's Lymphoma
- --Chronic Lymphocytic Leukemia
- --Rheumatoid Arthritis in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies
- -Wegener's Granulomatosis and Microscopic Polyangiitis in adult patients in combination with glucocorticoids
- Location
- Currently not on view
- Object Name
- pharmaceutical
- biological
- date made
- ca 2013
- product expiration date
- 2015-03
- maker
- Genentech, Inc.
- place made
- United States: California, South San Francisco
- Physical Description
- glass (overall material)
- plastic (overall material)
- cardboard (overall material)
- metal (overall material)
- rituximab, 100mg/10mL (overall ingredient)
- Measurements
- overall: 1 1/2 in x 2 3/4 in x 4 1/2 in; 3.81 cm x 6.985 cm x 11.43 cm
- overall: 4 5/8 in x 2 3/4 in x 1 1/2 in; 11.7475 cm x 6.985 cm x 3.81 cm
- ID Number
- 2013.0069.10
- catalog number
- 2013.0069.10
- accession number
- 2013.0069
- Credit Line
- Gift of Genentech, Inc.
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- Antibody Initiative: Monoclonal Antibodies
- Data Source
- National Museum of American History
Nominate this object for photography.
Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.
If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.
